Greg M. Arndt

This study identifies METTL1 gene dosage and catalytic activity as therapeutic targets in pediatric cancers, showing that inhibiting METTL1 synergizes with BCL-xL inhibitors.

This study identifies venetoclax-alisertib as a promising combination therapy for high-risk neuroblastoma, particularly effective in MYCN-amplified models, with improved survival and reduced toxicity.

This study identifies IRAK1 as a chemoresistance factor in neuroblastoma and shows synergy between IRAK1 inhibition and various drugs in preclinical models.